Compare BIAF & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIAF | VVOS |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 4.8M |
| IPO Year | 2022 | 2020 |
| Metric | BIAF | VVOS |
|---|---|---|
| Price | $0.40 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.75 |
| AVG Volume (30 Days) | ★ 1.8M | 895.8K |
| Earning Date | 05-14-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.76 |
| EPS | N/A | ★ N/A |
| Revenue | $7,900,000.00 | ★ $17,443,000.00 |
| Revenue This Year | $20.95 | $69.66 |
| Revenue Next Year | N/A | $48.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 14.49 | ★ 16.05 |
| 52 Week Low | $0.23 | $0.26 |
| 52 Week High | $13.50 | $5.11 |
| Indicator | BIAF | VVOS |
|---|---|---|
| Relative Strength Index (RSI) | 40.77 | 37.93 |
| Support Level | $0.33 | N/A |
| Resistance Level | $1.45 | $0.36 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 10.24 | 12.41 |
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.